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Minocycline and valproic acid are potential adjuvant therapies for the treatment of human immunodefi-
ciency virus (HIV)-associated cognitive impairment. The purpose of this study was to determine whether
minocycline alone or in combination with valproic acid affected atazanavir plasma concentrations. Twelve
adult HIV-infected subjects whose regimen included atazanavir (300 mg)-ritonavir (100 mg) daily for at least
4 weeks were enrolled. Each subject received atazanavir-ritonavir on day 1, atazanavir-ritonavir plus 100 mg
minocycline twice daily on days 2 to 15, and atazanavir-ritonavir plus 100 mg minocycline twice daily and 250
mg valproic acid twice daily on days 16 to 30 with meals. The subjects had 11 plasma samples drawn over a
dosing interval on days 1, 15, and 30. The coadministration of minocycline and valproic acid with atazanavir-
ritonavir was well tolerated in all 12 subjects (six male; mean [ standard deviation] age was 43.1 [8.2] years).
The geometric mean ratios (GMRs; 95% confidence interval [CI]) for the atazanavir area under the concen-
tration-time curve from 0 to 24 h at steady state (AUC0–24), the plasma concentration 24 h after the dose (Cmin),
and the maximum concentration during the dosing interval (Cmax) with and without minocycline were 0.67
(0.50 to 0.90), 0.50 (0.28 to 0.89), and 0.75 (0.58 to 0.95), respectively. Similar decreases in atazanavir exposure
were seen after the addition of valproic acid. The GMRs (95% CI) for atazanavir AUC0–24, Cmin, and Cmax with
and without minocycline plus valproic acid were 0.68 (0.43 to 1.06), 0.50 (0.24 to 1.06), and 0.66 (0.41 to 1.06),
respectively. Coadministration of neither minocycline nor minocycline plus valproic acid appeared to influence
the plasma concentrations of ritonavir (P > 0.2). Minocycline coadministration resulted in decreased ataza-
navir exposure, and there was no evidence that the addition of valproic acid mediated this effect.
Cognitive impairment is a common complication of human
immunodeficiency virus (HIV) infection, affecting one in five
patients, and HIV infection is currently the most common
cause of cognitive dysfunction in young people worldwide (2).
Although the incidence of HIV-associated cognitive impair-
ment has declined with the introduction of highly active anti-
retroviral therapy, the prevalence of this disorder will most
likely increase due to the increased life span of HIV-infected
individuals. Therefore, there is considerable interest in discov-
ering adjuvant medications to treat HIV-associated cognitive
impairment (6, 15).
Minocycline and valproic acid are both candidates for ad-
junctive therapy. Valproic acid may delay cognitive and behav-
ioral changes associated with HIV infection through a number
of mechanisms, including the modulation of glycogen synthase
kinase 3-beta (8, 16). Minocycline is a tetracycline antimicro-
bial agent that has been shown in vitro and in animal models
to mitigate a number of pathways that may lead to cognitive
impairment, including microglia activation, glutamate toxic-
ity, and caspase-independent and -dependent mitochondrion-
mediated cell death (21). In addition, minocycline has been
shown to delay the course of disease in mouse models of
Huntington’s disease and amyotrophic lateral sclerosis (19).
Minocycline has also been shown to provide neuroprotec-
tion as well as reduce viral load in cerebral spinal fluid and
brain homogenates in simian immunodeficiency virus-in-
fected macaques that develop encephalitis, an animal model
that recapitulates significant pathological features associ-
ated with HIV dementia (23). The above data have led to the
implementation of a minocycline clinical trial in HIV-infected
individuals with cognitive impairment (AIDS Clinical Trials
Group protocol A5235).
In light of numerous reported protease inhibitor drug inter-
actions and evidence supporting a correlation between pro-
tease inhibitor plasma concentrations and virologic response, it
is important to consider the potential for protease inhibitor
drug interactions before performing clinical trials (1, 4, 9, 10).
This study was designed in response to interest in developing
combination adjunctive therapy for the treatment of HIV-
associated cognitive impairment. Having previously published
results that failed to show a negative influence of valproic acid
on lopinavir plasma concentrations, we decided to focus this
study on the potential effects of minocycline with and without
valproic acid (7). Since study of the entire class of protease
inhibitors is cost prohibitive, we selected atazanavir based on
its frequent use as a part of highly active antiretroviral therapy
at our clinic. The purpose of this study was to determine
whether minocycline alone or in combination with valproic
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acid would alter the atazanavir disposition when boosted by
ritonavir in HIV-infected adults.
MATERIALS AND METHODS
Study subjects. Subjects were recruited from the North East AIDS Dementia
cohort and the AIDS Clinical Trials Unit at the University of Rochester. HIV-
infected subjects 18 years or older who met the criteria, including a stable
antiretroviral regimen that included atazanavir and ritonavir for at least 4 weeks,
were eligible for enrollment. Women who were pregnant or nursing and subjects
taking a nonnucleoside reverse transcriptase inhibitor or any medication or
herbal supplement known or suspected to interfere with the cytochrome P-450
(CYP450) isoenzyme system that was not cleared by the investigator were ex-
cluded.
Study design. The Research Subject Review Board at the University of Roch-
ester approved this study, and all subjects were required to provide informed
consent before any study procedures were initiated. All subjects received ataza-
navir (300 mg)-ritonavir (100 mg) once daily throughout the study, and all study
drugs were given together with meals. Subjects received 100 mg minocycline
twice daily on days 2 to 15 and 100 mg minocycline plus 250 mg valproic acid
twice daily on days 16 to 30. Subjects arrived in the General Clinical Research
Center (GCRC) in the morning on days 1, 15, and 30 after fasting since midnight
the night before and received study drugs within 5 min of eating a standardized
light breakfast. Each subject could choose from the following breakfast menu:
toast (with or without jelly), bagel, an apple or apple sauce, banana, apple juice,
and 1 cup of 1% milk. Dietary restrictions included no grapefruit-containing
products within 3 days of the first visit and until discharge from the study and no
citrus products on days 1, 2, 14, 15, 16, 30, and 31. Blood samples were drawn
predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 h after the morning dose of the
study drug. Most subjects preferred staying overnight at the GCRC, while a few
opted for discharge after the sample collection at 10 h and returned the next day
for the 24-h-postdose sample collection. Minocycline and valproic acid were
dispensed by the investigational pharmacy at the University of Rochester, and
adherence was determined by subjects reporting the last three times of study
drug administration before arrival at the GCRC.
Drug assays. Atazanavir and ritonavir plasma concentrations were measured
using a New York State-certified method for plasma protease inhibitor quanti-
tation utilized within the Pharmacotherapy Research Center Core Analytical
Laboratory at the University at Buffalo (11). The lower limit of quantitation for
atazanavir was 100 ng/ml. Samples with ritonavir concentrations that were below
the lower limit of quantification (200 ng/ml) were measured using a previously
published reverse-phase high-performance liquid chromatography assay at the
University of North Carolina Center for AIDS Research, for which the lower
limit of quantitation was 25 ng/ml (14).
Pharmacokinetic and statistical analyses. Standard noncompartmental tech-
niques were used to calculate pharmacokinetic parameters using WinNonlin
version 4.1 (Pharsight, Palo Alto, CA). The area under the concentration-time
curve was determined using the linear trapezoidal rule for increasing values and
the log trapezoidal rule for decreasing values, and the maximum observed con-
centration during the dosing interval was determined by visual inspection. If the
sample drawn at the end of the dosing interval was not available or had a higher
concentration than the sample collected at the previous time point, the concen-
tration reported was determined by extrapolation using the estimated terminal
elimination rate. The log transforms of pharmacokinetic parameters were com-
pared between visits by using two-sided paired t tests at the 0.05 level of signif-
icance, corresponding with 95% confidence intervals (CI) for the geometric
mean ratio (GMR).
RESULTS
Minocycline and valproic acid coadministration was well tol-
erated in all 12 subjects who completed the study. Only two
subjects experienced mild nausea which was self limiting. Data
for gender, age, antiretroviral use, ethnicity, CD4 cell count,
and viral load are given in Table 1. Subjects were allowed to
receive nonantiretroviral medications at the discretion of the
investigators as long as the medication was continued through-
out the study. Concomitant nonantiretroviral therapy included
three subjects receiving sulfamethoxazole-trimethoprim and
two subjects receiving amitriptyline, gabapentin, or an albu-
terol inhaler. Nonantiretroviral therapy taken by at least one
subject throughout the study included fenofibrate, rosiglita-
zone, enfuvirtide, pravastatin, atorvastatin, ranitidine, nicotine
replacement, acyclovir, vancomycin for a Mediport implant-
able port infection, paroxetine, medroxyprogesterone, spirono-
lactone, estradiol, trazodone, venlafaxine, dapsone, clonazepam,
olanzapine, ferrous sulfate, escitalopram, loratadine, docusate,
oxybutynin, erythropoietin, peginterferon alfa-2a, ribavirin, aspi-
rin, alendronate, and testosterone.
Concomitant administration of minocycline decreased atazana-
vir plasma concentrations (Fig. 1 and Table 2). Minocycline
coadministration resulted in a 33% decrease in the atazanavir
area under the plasma concentration-time curve at steady state
(AUC0–24; P  0.014), a 50% decrease in the plasma concen-
tration 24 h after the dose (Cmin; P  0.022), and a 25%
decrease in the maximum concentration during the dosing
interval (Cmax; P  0.024). The GMRs (95% CI) for atazanavir
AUC0–24, Cmin, and Cmax with and without minocycline were
0.67 (0.50 to 0.90), 0.50 (0.28 to 0.89), and 0.75 (0.58 to 0.95),
respectively. There was no evidence of a differential effect by
baseline viral load status. The GMRs for AUC0–24 were 0.66
and 0.68 for each subgroup of six patients with HIV-1 RNA
levels below and above 50 copies/ml, respectively. Although
this study was not designed to determine whether alterations in
plasma concentration would result in an altered viral load, of
the 11 subjects who had viral loads reported on both the
screening and the final visit, only 1 subject had a slight increase
in viral load (50 to 78 cells/ml) on the final visit, which was most
likely a clinically insignificant blip.
Similar decreases in atazanavir exposure were seen after the
addition of valproic acid (Table 2). The GMRs (95% CI) for
atazanavir AUC0–24, Cmin, and Cmax with and without minocy-
cline plus valproic acid were 0.68 (0.43 to 1.06; P  0.080), 0.50
(0.24 to 1.06; P  0.069), and 0.66 (0.41 to 1.06; P  0.078),
respectively. When the coadministration of minocycline is
compared to the coadministration of minocycline plus valproic
acid, the GMRs (95% CI) for atazanavir AUC0–24, Cmin, and
Cmax were 1.00 (0.57 to 1.77; P  0.99), 1.01 (0.37 to 2.8; P 
TABLE 1. Demographics and baseline clinical variablesa
Parameter Value
Median age (IQR) (yr) ............................................................... 43.5 (37.8 to 46.5)
% of patients of male gender .................................................... 50




Median CD4 cell count/mm3 (IQR) .........................................399 (164 to 517)
Median no. of HIV RNA copies/ml (IQR) .............................399 (139 to 1,037)
% of patients with 50 copies of HIV RNA/ml..................... 50










a Table data are based on 12 subjects included in the pharmacokinetic analysis.
IQR, interquartile range.
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0.99), and 0.89 (0.53 to 1.48; P  0.63), respectively. The
atazanavir half-life did not appear to be dependent on the drug
regimen. The GMRs (95% CI) for atazanavir half-life with and
without minocycline or minocycline plus valproic acid were
0.73 (0.52 to 1.02) and 0.85 (0.67 to 1.09), respectively.
We also analyzed the influence of minocycline and minocy-
cline plus valproic acid coadministration on the plasma con-
centrations of ritonavir. Nine of the 12 subjects studied were
included in the ritonavir pharmacokinetic analysis. One subject
was receiving saquinavir, which interfered with the ritonavir
assay, and two subjects had samples with plasma concentra-
tions of ritonavir that were reported to be below the limit of
detection. All of these subjects were observed to receive ataza-
navir and ritonavir during their visits, and atazanavir exposure
was lower during minocycline coadministration in this subset of
nine subjects (atazanavir AUC0–24 GMR [95% CI]  0.68
[0.52 to 0.88]). Coadministration of minocycline or minocy-
cline plus valproic acid did not have a statistically significant
influence on ritonavir plasma concentrations (Table 2 and Fig.
2; P was 0.2 for all comparisons). The GMRs (95% CI) for
ritonavir AUC0–24, Cmin, and Cmax with and without minocy-
cline were 0.90 (0.50 to 1.60), 1.23 (0.59 to 2.53), and 0.95 (0.54
to 1.68), respectively, while the GMRs (95% CI) for ritonavir
AUC0–24, Cmin, and Cmax with and without minocycline plus
valproic acid were 0.86 (0.39 to 1.90), 1.16 (0.38 to 3.60), and
0.87 (0.40 to 1.90), respectively.
DISCUSSION
We found that minocycline decreased atazanavir plasma
concentrations in HIV-infected adults, and we did not see any
evidence that valproic acid would influence this interaction.
Most protease inhibitors, including atazanavir and ritonavir,
are substrates for CYP450 enzymes and transporter proteins,
such as P glycoprotein, making them particularly susceptible to
drug interactions involving drug absorption, tissue distribution,
metabolism, and elimination (13). Although there is some ev-
idence that minocycline is at least partially metabolized by
CYP450 enzymes, there is little evidence that minocycline in-
fluences the disposition of drugs by inducing this enzyme sys-
tem (3, 17). There are case reports of minocycline interacting
with theophylline, but minocycline increased theophylline ex-
posure and theophylline is metabolized primarily by a CYP450
enzyme (CYP1A2) that is not thought to influence the dispo-
sition of atazanavir (12, 20). Like other tetracyclines, minocy-
cline has the potential to decrease exposure to oral contracep-
FIG. 1. Atazanavir plasma concentrations. Results shown are the means  standard errors of atazanavir plasma concentrations for 12 subjects.
Circles, squares, and diamonds represent atazanavir alone, atazanavir plus minocycline, and atazanavir plus minocycline and valproic acid,
respectively.
TABLE 2. Atazanavir and ritonavir pharmacokinetic resultsa
Drug(s) AUC (h  g/ml) Cmin (g/ml) Cmax (g/ml) Half-life (h)
Atazanavir 53.5 (35.1–67.9) 0.739 (0.247–1.37) 5.13 (2.98–6.48) 11.0 (7.88–15.7)
Atazanavir plus minocycline 33.1 (24.7–42.4) 0.455 (0.363–0.538) 3.40 (2.61–4.82) 7.93 (7.12–9.82)
Atazanavir plus minocycline
and valproic acid
33.5 (14.2–75.2) 0.576 (0.107–1.47) 2.60 (1.77–6.61) 10.4 (5.35–16.1)
Ritonavir 9.60 (6.07–14.6) 0.0753 (0.0299–0.147) 0.957 (0.90–1.95) 5.40 (5.26–5.64)
Ritonavir plus minocycline 8.19 (6.21–11.2) 0.0655 (0.0522–0.112) 0.990 (0.946–1.74) 6.64 (5.33–6.85)
Ritonavir plus minocycline
and valproic acid
7.27 (6.00–7.55) 0.0735 (0.0277–0.113) 0.884 (0.755–1.40) 4.40 (4.03–5.29)
a The values reported are medians (interquartile ranges) for 12 subjects (atazanavir) and 9 subjects (ritonavir) who had measurable results.
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tives; however, the interference of enterohepatic recirculation
via the alteration of bacterial flora is the purported mechanism
of this interaction (24). Although tetracyclines have been
shown to increase the absorption of digoxin, a P-glycoprotein
substrate, this interaction is thought to be due to decreased
bacterial metabolism rather than to an influence on efflux
pump activity (25).
Protease inhibitors are weak bases; therefore, elevations in
gastric pH may lead to decreased drug solubility and absorp-
tion. Although there is evidence that metal cations chelate with
tetracyclines to form unabsorbable complexes and that antac-
ids may alter tetracycline absorption by increasing gastric pH,
we were unable to find any evidence that minocycline binds to
atazanavir or alters gastric pH (5, 22). Since the half-life was
not significantly altered, decreased absorption may be the most
likely explanation for the effect of minocycline on atazanavir
plasma concentrations. However, our inability to detect an
influence on the half-life was limited by the sampling strategy
in which no samples were drawn between 10 and 24 h after the
dose and by the small sample size. Since atazanavir absorption
may be more sensitive than the absorption of other protease
inhibitors to elevated gastric pH, more study is needed to
determine whether minocycline will influence the absorption
of other protease inhibitors.
Since ritonavir boosts atazanavir exposure, we also investi-
gated the potential for minocycline to influence atazanavir
indirectly by altering ritonavir plasma concentrations. Neither
minocycline nor minocycline plus valproic acid coadministra-
tion resulted in a statistically significant change in any of the
ritonavir pharmacokinetic parameters tested. However, com-
parisons between visits were limited by the inclusion of only 9
of the 12 subjects enrolled. Although we observed a net ten-
dency for higher atazanavir and ritonavir concentrations dur-
ing valproic acid coadministration (Fig. 1 and 2), neither the
atazanavir nor the ritonavir AUC0–24 appears to be influenced
by valproic acid coadministration (Table 2). More study is
necessary before concluding that minocycline coadministration
does not influence ritonavir exposure.
There are a number of additional limitations to this study.
Since we included HIV-infected adults and did not attempt to
alter their medications, some subjects were receiving concom-
itant medication that may have influenced atazanavir plasma
concentrations. However, the influence of concomitant medi-
cations was limited by instructing subjects to continue all con-
comitant medications throughout the study and using a paired
design. Although one subject received saquinavir and a gastric
acid buffering agent, ranitidine, a comparison of atazanavir
results (atazanavir with and without minocycline) to those ob-
tained with this subject excluded showed that inclusion of this
subject did not appear to influence atazanavir AUC0–24 (P 
0.014 versus P  0.029), Cmin (P  0.022 versus P  0.039), or
Cmax (P  0.024 versus P  0.05) results. Another limitation of
this study is the inability to determine whether atazanavir-
ritonavir influences valproic acid exposure. Ritonavir may in-
duce the glucuronidation of valproic acid. Sheehan and col-
leagues reported a clinically significant case of decreased
valproic acid concentration during lopinavir-ritonavir coad-
ministration (18). Although we reported no evidence that lopi-
navir-ritonavir decreased valproic acid trough plasma concen-
trations during a previous study, both of our studies used a low
dose of valproic acid (7). There is the potential that higher
doses of valproic acid may influence the effect of minocycline
on atazanavir and ritonavir or that clinically significant de-
creases in valproic acid exposure may be seen at higher doses.
Lastly, the high degree of inter- and intrapatient variabilities in
atazanavir and ritonavir exposures may have limited our ability
to find a difference when regimens were compared.
In summary, minocycline coadministration resulted in de-
creased atazanavir exposure, and there was no evidence that
the addition of valproic acid mediated this effect or that this
effect was indirectly influenced through altered ritonavir expo-
sure. Since the mechanism of this interaction is unknown, more
FIG. 2. Ritonavir plasma concentrations. Results shown are the means  standard errors of ritonavir plasma concentrations for nine subjects.
Circles, squares, and diamonds represent ritonavir alone, ritonavir plus minocycline, and ritonavir plus minocycline and valproic acid, respectively.
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studies are necessary to determine whether minocycline would
alter the plasma concentrations of other protease inhibitors.
Lastly, a longer period of observation is needed to determine
whether the pharmacokinetic interaction observed in this study
influences treatment response.
ACKNOWLEDGMENTS
This work was supported by grant P01 MH64570; in part by a
General Clinical Research Center Grant, 5M01-RR 00044, from the
National Center for Research Resources, NIH, and the University of
North Carolina at Chapel Hill Center for AIDS Research (CFAR);
NIH-funded program grant P30 AI50410; and the University at Buffalo
Pharmacotherapy Research Center Core Analytical Laboratory.
REFERENCES
1. Acosta, E. P., J. G. Gerber, and the Adult Pharmacology Committee of the
AIDS Clinical Trials Group. 2002. Position paper on therapeutic drug mon-
itoring of antiretroviral agents. AIDS Res. Hum. Retrovir. 18:825–834.
2. Ances, B. M., and R. J. Ellis. 2007. Dementia and neurocognitive disorders
due to HIV-1 infection. Semin. Neurol. 27:86–92.
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